デフォルト表紙
市場調査レポート
商品コード
1193145

トキソプラズマ症治療市場:タイプ別、投与経路別、流通チャネル別:世界の機会分析および産業予測、2021-2031年

Toxoplasmosis Treatment Market By Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: | 発行: Allied Market Research | ページ情報: 英文 210 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
トキソプラズマ症治療市場:タイプ別、投与経路別、流通チャネル別:世界の機会分析および産業予測、2021-2031年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 210 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のトキソプラズマ症治療市場は、2021年に6億8311万米ドル、2031年には10億9388万米ドルに達し、2022年から2031年までCAGR4.8%を記録すると予測されます。

トキソプラズマ症は、世界で最も一般的な寄生虫の1つであるトキソプラズマ・ゴンジーの寄生により発症する病気です。この感染は通常、加熱不十分な汚染された肉を食べること、感染した猫の糞便からの曝露、または妊娠中の母子感染によって起こります。トキソプラズマ症は、人によってはインフルエンザのような症状を引き起こすことがありますが、感染者の大半は症状や徴候を示すことはありません。

トキソプラズマ症治療薬の世界市場の成長は、主に食中毒の流行が原因となっています。また、トキソプラズマ症治療と診断における技術的進歩が市場成長を後押ししています。さらに、米国などの新興諸国におけるトキソプラズマ症治療に関する認知度の向上が、市場成長をさらに後押ししています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 トキソプラズマ症治療市場:タイプ別

  • 概要
    • 市場規模および予測
  • 後天性トキソプラズマ症
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 先天性トキソプラズマ症
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第5章 トキソプラズマ症治療薬市場:投与経路別

  • 概要
    • 市場規模および予測
  • 経口投与
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 非経口剤
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第6章 トキソプラズマ症治療市場:流通チャネル別

  • 概要
    • 市場規模・予測
  • 病院薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • ドラッグストア、小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • オンラインプロバイダー
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第7章 トキソプラズマ症治療市場:地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米市場規模・予測:タイプ別
    • 北米市場規模・予測:投与経路別
    • 北米市場規模・予測:流通チャネル別
    • 北米市場規模・予測:国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州の市場規模・予測:タイプ別
    • 欧州市場規模・予測:投与経路別
    • 欧州市場規模・予測:流通チャネル別
    • 欧州市場規模・予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測:タイプ別
    • アジア太平洋地域の市場規模・予測:投与経路別
    • アジア太平洋地域の市場規模・予測:流通チャネル別
    • アジア太平洋地域の市場規模・予測:国別
      • 日本
      • 中国
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測:タイプ別
    • LAMEAの市場規模・予測:投与経路別
    • LAMEAの市場規模・予測:流通チャネル別
    • LAMEAの市場規模・予測:国別
      • ブラジル
      • サウジアラビア
      • 南アラビア
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • Alvogen
  • Dr Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Limited
  • Vyera Pharmaceuticals LLC
  • Mangalam Drugs and Organics Ltd.
  • Oakrum Pharma
  • Kaiser Permanente
  • Zorish Healthcare Private Limited
  • omicron pharmaceuticals
  • Manus Aktteva Biopharma LLP
図表

LIST OF TABLES

  • TABLE 1. GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. TOXOPLASMOSIS TREATMENT MARKET FOR ACQUIRED TOXOPLASMOSIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. TOXOPLASMOSIS TREATMENT MARKET FOR ACQUIRED TOXOPLASMOSIS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. TOXOPLASMOSIS TREATMENT MARKET FOR CONGENITAL TOXOPLASMOSIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. TOXOPLASMOSIS TREATMENT MARKET FOR CONGENITAL TOXOPLASMOSIS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. TOXOPLASMOSIS TREATMENT MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. TOXOPLASMOSIS TREATMENT MARKET FOR ORAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. TOXOPLASMOSIS TREATMENT MARKET FOR PARENTERAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. TOXOPLASMOSIS TREATMENT MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. GLOBAL TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. TOXOPLASMOSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. TOXOPLASMOSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. TOXOPLASMOSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. TOXOPLASMOSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. TOXOPLASMOSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. TOXOPLASMOSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. TOXOPLASMOSIS TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. U.S. TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. U.S. TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. U.S. TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. CANADA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. CANADA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. CANADA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. MEXICO TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. MEXICO TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. MEXICO TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. GERMANY TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. GERMANY TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. GERMANY TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. FRANCE TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. FRANCE TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. FRANCE TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. UK TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. UK TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. UK TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. ITALY TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. ITALY TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. ITALY TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. SPAIN TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. SPAIN TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. SPAIN TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. JAPAN TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. JAPAN TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. JAPAN TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. CHINA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. CHINA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. CHINA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. INDIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. INDIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. INDIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. BRAZIL TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. BRAZIL TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. BRAZIL TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92.ALVOGEN: COMPANY SNAPSHOT
  • TABLE 93.ALVOGEN: OPERATING SEGMENTS
  • TABLE 94.ALVOGEN: PRODUCT PORTFOLIO
  • TABLE 95.ALVOGEN: NET SALES
  • TABLE 96.ALVOGEN: KEY STRATERGIES
  • TABLE 97.DR REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 98.DR REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 99.DR REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 100.DR REDDY'S LABORATORIES LTD.: NET SALES
  • TABLE 101.DR REDDY'S LABORATORIES LTD.: KEY STRATERGIES
  • TABLE 102.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 103.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
  • TABLE 104.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 105.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES
  • TABLE 106.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 107.VYERA PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 108.VYERA PHARMACEUTICALS LLC: OPERATING SEGMENTS
  • TABLE 109.VYERA PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 110.VYERA PHARMACEUTICALS LLC: NET SALES
  • TABLE 111.VYERA PHARMACEUTICALS LLC: KEY STRATERGIES
  • TABLE 112.MANGALAM DRUGS AND ORGANICS LTD.: COMPANY SNAPSHOT
  • TABLE 113.MANGALAM DRUGS AND ORGANICS LTD.: OPERATING SEGMENTS
  • TABLE 114.MANGALAM DRUGS AND ORGANICS LTD.: PRODUCT PORTFOLIO
  • TABLE 115.MANGALAM DRUGS AND ORGANICS LTD.: NET SALES
  • TABLE 116.MANGALAM DRUGS AND ORGANICS LTD.: KEY STRATERGIES
  • TABLE 117.OAKRUM PHARMA: COMPANY SNAPSHOT
  • TABLE 118.OAKRUM PHARMA: OPERATING SEGMENTS
  • TABLE 119.OAKRUM PHARMA: PRODUCT PORTFOLIO
  • TABLE 120.OAKRUM PHARMA: NET SALES
  • TABLE 121.OAKRUM PHARMA: KEY STRATERGIES
  • TABLE 122.KAISER PERMANENTE: COMPANY SNAPSHOT
  • TABLE 123.KAISER PERMANENTE: OPERATING SEGMENTS
  • TABLE 124.KAISER PERMANENTE: PRODUCT PORTFOLIO
  • TABLE 125.KAISER PERMANENTE: NET SALES
  • TABLE 126.KAISER PERMANENTE: KEY STRATERGIES
  • TABLE 127.ZORISH HEALTHCARE PRIVATE LIMITED: COMPANY SNAPSHOT
  • TABLE 128.ZORISH HEALTHCARE PRIVATE LIMITED: OPERATING SEGMENTS
  • TABLE 129.ZORISH HEALTHCARE PRIVATE LIMITED: PRODUCT PORTFOLIO
  • TABLE 130.ZORISH HEALTHCARE PRIVATE LIMITED: NET SALES
  • TABLE 131.ZORISH HEALTHCARE PRIVATE LIMITED: KEY STRATERGIES
  • TABLE 132.OMICRON PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 133.OMICRON PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 134.OMICRON PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 135.OMICRON PHARMACEUTICALS: NET SALES
  • TABLE 136.OMICRON PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 137.MANUS AKTTEVA BIOPHARMA LLP: COMPANY SNAPSHOT
  • TABLE 138.MANUS AKTTEVA BIOPHARMA LLP: OPERATING SEGMENTS
  • TABLE 139.MANUS AKTTEVA BIOPHARMA LLP: PRODUCT PORTFOLIO
  • TABLE 140.MANUS AKTTEVA BIOPHARMA LLP: NET SALES
  • TABLE 141.MANUS AKTTEVA BIOPHARMA LLP: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.TOXOPLASMOSIS TREATMENT MARKET SEGMENTATION
  • FIGURE 2.TOXOPLASMOSIS TREATMENT MARKET,2021-2031
  • FIGURE 3.TOXOPLASMOSIS TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.TOXOPLASMOSIS TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.TOXOPLASMOSIS TREATMENT MARKET,BY TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ACQUIRED TOXOPLASMOSIS TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CONGENITAL TOXOPLASMOSIS TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.TOXOPLASMOSIS TREATMENT MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ORAL TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF PARENTERAL TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.TOXOPLASMOSIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS TOXOPLASMOSIS TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.TOXOPLASMOSIS TREATMENT MARKET BY REGION,2021
  • FIGURE 23.U.S. TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 24.CANADA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 25.MEXICO TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 26.GERMANY TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.FRANCE TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.UK TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.ITALY TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.SPAIN TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.REST OF EUROPE TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.JAPAN TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.CHINA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.INDIA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.AUSTRALIA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.SOUTH KOREA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.REST OF ASIA-PACIFIC TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.BRAZIL TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.SAUDI ARABIA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH ARABIA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF LAMEA TOXOPLASMOSIS TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46.COMPETITIVE DASHBOARD
  • FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 48.ALVOGEN.: NET SALES ($MILLION)
  • FIGURE 49.DR REDDY'S LABORATORIES LTD..: NET SALES ($MILLION)
  • FIGURE 50.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)
  • FIGURE 51.VYERA PHARMACEUTICALS LLC.: NET SALES ($MILLION)
  • FIGURE 52.MANGALAM DRUGS AND ORGANICS LTD..: NET SALES ($MILLION)
  • FIGURE 53.OAKRUM PHARMA.: NET SALES ($MILLION)
  • FIGURE 54.KAISER PERMANENTE.: NET SALES ($MILLION)
  • FIGURE 55.ZORISH HEALTHCARE PRIVATE LIMITED.: NET SALES ($MILLION)
  • FIGURE 56.OMICRON PHARMACEUTICALS.: NET SALES ($MILLION)
  • FIGURE 57.MANUS AKTTEVA BIOPHARMA LLP.: NET SALES ($MILLION)
目次
Product Code: A15647

The global toxoplasmosis treatment market was valued at $683.11 million in 2021, and is projected to reach $1,093.88 million by 2031, registering a CAGR of 4.8% from 2022 to 2031. Toxoplasmosis is a disease that occurs due to Toxoplasma gondii parasite, which is one of the world's most common parasites. This infection usually occurs by eating undercooked contaminated meat, exposure from infected cat feces, or mother-to-child transmission during pregnancy. Toxoplasmosis may cause flu-like symptoms in some people, however majority of those infected never show any signs or symptoms.

The growth of global toxoplasmosis treatment market is majorly driven by increase in prevalence of foodborne illness. In addition, technological advancement in treatment and diagnosis for toxoplasmosis disease propels the market growth. Furthermore, increase in awareness regarding toxoplasmosis treatment in developed countries such as the U.S. further fuels the market growth.

In addition, increase in prevalence of HIV across the globe has increased the risk of toxoplasma gondii infection due to less immune response in HIV infected patients that lead to rise in demand for toxoplasmosis treatment and propels the market growth. For instance, according to the World Health Organization (WHO), by the end of 2021, around 38.4 million people were living with HIV across the globe, therefore it is expected to increase the prevalence of toxoplasmosis infection among the global population that drives the market growth.

Furthermore, surge in healthcare, industrial development, and investments by the government and private organizations in Asia-Pacific, along with rise in awareness regarding toxoplasmosis disease is anticipated to positively impact the market during the forecast period. Moreover, product launch for toxoplasmosis treatment by the key market players are the boosting factors for the market growth. For instance, Dr. Reddy's Laboratories Ltd. announced the launch of pyrimethamine tablet USP, 25 mg, approved by the U.S. Food and Drug Administration (USFDA) for the treatment of toxoplasmosis.

However, side effects of toxoplasmosis drugs and high cost of treatment hinder the market growth. Conversely, rise in product approvals for toxoplasmosis treatment is anticipated to provide lucrative opportunities to the market players.

The toxoplasmosis treatment market is segmented on the basis of type, route of administration, distribution channel, and region. By type, the market is categorized into acquired toxoplasmosis and congenital toxoplasmosis. On the basis of route of administration, the market is segregated into oral and parenteral. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global toxoplasmosis treatment market are Alvogen, Dr. Reddy's Laboratories Ltd., Kaiser Permanente, Mangalam Drugs and Organics Ltd., Manus Aktteva Biopharma LLP, Oakrum Pharma, Omicron pharmaceuticals, Teva Pharmaceutical Industries Ltd., Vyera Pharmaceuticals LLC, and Zorish Healthcare Private Limited. 

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the toxoplasmosis treatment market analysis from 2021 to 2031 to identify the prevailing toxoplasmosis treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the toxoplasmosis treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global toxoplasmosis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Acquired Toxoplasmosis
  • Congenital Toxoplasmosis

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Arabia
    • Rest of LAMEA
  • Key Market Players
    • Alvogen
    • Dr Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Limited
    • Vyera Pharmaceuticals LLC
    • Mangalam Drugs and Organics Ltd.
    • Oakrum Pharma
    • Kaiser Permanente
    • Zorish Healthcare Private Limited
    • omicron pharmaceuticals
    • Manus Aktteva Biopharma LLP

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: TOXOPLASMOSIS TREATMENT MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Acquired Toxoplasmosis
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Congenital Toxoplasmosis
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: TOXOPLASMOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Oral
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Parenteral
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: TOXOPLASMOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Drug Stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: TOXOPLASMOSIS TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Type
    • 7.2.3 North America Market size and forecast, by Route of Administration
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Type
      • 7.2.5.1.3 Market size and forecast, by Route of Administration
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Type
      • 7.2.5.2.3 Market size and forecast, by Route of Administration
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Type
      • 7.2.5.3.3 Market size and forecast, by Route of Administration
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Type
    • 7.3.3 Europe Market size and forecast, by Route of Administration
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Type
      • 7.3.5.1.3 Market size and forecast, by Route of Administration
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Type
      • 7.3.5.2.3 Market size and forecast, by Route of Administration
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Type
      • 7.3.5.3.3 Market size and forecast, by Route of Administration
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Type
      • 7.3.5.4.3 Market size and forecast, by Route of Administration
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Type
      • 7.3.5.5.3 Market size and forecast, by Route of Administration
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Type
      • 7.3.5.6.3 Market size and forecast, by Route of Administration
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Type
      • 7.4.5.1.3 Market size and forecast, by Route of Administration
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Type
      • 7.4.5.2.3 Market size and forecast, by Route of Administration
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Type
      • 7.4.5.3.3 Market size and forecast, by Route of Administration
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Type
      • 7.4.5.4.3 Market size and forecast, by Route of Administration
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Type
      • 7.4.5.5.3 Market size and forecast, by Route of Administration
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Type
      • 7.4.5.6.3 Market size and forecast, by Route of Administration
      • 7.4.5.6.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Type
    • 7.5.3 LAMEA Market size and forecast, by Route of Administration
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Type
      • 7.5.5.1.3 Market size and forecast, by Route of Administration
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Type
      • 7.5.5.2.3 Market size and forecast, by Route of Administration
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Arabia
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Type
      • 7.5.5.3.3 Market size and forecast, by Route of Administration
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Type
      • 7.5.5.4.3 Market size and forecast, by Route of Administration
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Alvogen
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Dr Reddy's Laboratories Ltd.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Teva Pharmaceutical Industries Limited
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Vyera Pharmaceuticals LLC
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Mangalam Drugs and Organics Ltd.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Oakrum Pharma
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Kaiser Permanente
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Zorish Healthcare Private Limited
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 omicron pharmaceuticals
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Manus Aktteva Biopharma LLP
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments